By Jason Hartman, VP, Operations Scaling sterile injectable programs from early development to commercial supply is a complex undertaking shaped by far more than process know-how alone. It requires a deliberate foundation of infrastructure, equipment strategy, and technology that can support reliability, flexibility, and regulatory rigor as products evolve. This article explores how these elements come together to enable consistent performance across the product lifecycle.